Prevention of HIV-1 Infection with Early Antiretroviral Therapy
Myron S. Cohen, Ying Qing Chen, Marybeth McCauley, Theresa Gamble, Mina C. Hosseinipour, Nagalingeswaran Kumarasamy, James Gita Hakim, Johnstone Kumwenda, Beatriz Gilda Jegerhorn Grinsztejn, José Henrique Pilotto, Sheela Godbole, Sanjay Madhav Mehendale, Suwat Chariyalertsak, Breno Riegel Santos, Kenneth Hugh Mayer, Irving Hoffman, Susan H. Eshleman, Estelle Piwowar‐Manning, Lei Wang, Joseph M. Makhema, Lisa A. Mills, Guy de Bruyn, Ian Sanne, Joseph J. Eron, Joel E. Gallant, Diane V. Havlir, Susan Swindells, Heather Jane Ribaudo, Vanessa Elharrar, David Burns, Taha E. Taha, Karin Nielsen‐Saines, David D. Celentano, Max Essex, Thomas R. Fleming
New England Journal of Medicine · 2011 · 7,006 citationsOpen access
Abstract
BACKGROUND: Antiretroviral therapy that reduces viral replication could limit the transmission of human immunodeficiency virus type 1 (HIV-1) in serodiscordant couples. METHODS: In nine countries, we enrolled 1763 couples in which one partner was HIV-1-positive and the other was HIV-1-negative; 54% of the subjects were from Africa, and 50% of infected partners were men. HIV-1-infected subjects with CD4 counts between 350 and 550 cells per cubic millimeter were randomly assigned in a 1:1 ratio to receive antiretroviral therapy either immediately (early therapy) or after a decline in the CD4 count or the onset of HIV-1-related symptoms (delayed therapy). The primary prevention end point was linked HIV-1 transmission in HIV-1-negative partners. The primary clinical end point was the earliest occurrence of pulmonary tuberculosis, severe bacterial infection, a World Health Organization stage 4 event, or death. RESULTS: As of February 21, 2011, a total of 39 HIV-1 transmissions were observed (incidence rate, 1.2 per 100 person-years; 95% confidence interval [CI], 0.9 to 1.7); of these, 28 were virologically linked to the infected partner (incidence rate, 0.9 per 100 person-years, 95% CI, 0.6 to 1.3). Of the 28 linked transmissions, only 1 occurred in the early-therapy group (hazard ratio, 0.04; 95% CI, 0.01 to 0.27; P<0.001). Subjects receiving early therapy had fewer treatment end points (hazard ratio, 0.59; 95% CI, 0.40 to 0.88; P=0.01). CONCLUSIONS: The early initiation of antiretroviral therapy reduced rates of sexual transmission of HIV-1 and clinical events, indicating both personal and public health benefits from such therapy. (Funded by the National Institute of Allergy and Infectious Diseases and others; HPTN 052 ClinicalTrials.gov number, NCT00074581.).
Cite this paper
Cohen, M. S., Chen, Y. Q., McCauley, M., Gamble, T., Hosseinipour, M. C., Kumarasamy, N., Hakim, J. G., Kumwenda, J., Grinsztejn, B. G. J., Pilotto, J. H., Godbole, S., Mehendale, S. M., Chariyalertsak, S., Santos, B. R., Mayer, K. H., Hoffman, I., Eshleman, S. H., Piwowar‐Manning, E., Wang, L., … Fleming, T. R. (2011). Prevention of HIV-1 infection with early antiretroviral therapy. New England Journal of Medicine, 365(6), 493–505. https://doi.org/10.1056/nejmoa1105243
Read it with every claim anchored
Add this paper to a project, ask questions of it, and get answers that point to the exact passage.
Start freeRelated papers
- AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility2009
- 1993 Revised Classification System for HIV Infection and Expanded Surveillance Case Definition for AIDS Among Adolescents and Adults1993
- HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor1996
- Reduction of Maternal-Infant Transmission of Human Immunodeficiency Virus Type 1 with Zidovudine Treatment1994
- HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time1996
Metadata from OpenAlex (CC0). Citations are generated from the published record.